Loading…

Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease

Mitochondrial dysfunction and oxidative stress are extensively linked to Parkinson’s disease (PD) pathogenesis. Melatonin is a pleiotropic molecule with antioxidant and neuroprotective effects. The aim of this study was to evaluate the effect of melatonin on oxidative stress markers, mitochondrial c...

Full description

Saved in:
Bibliographic Details
Published in:Oxidative medicine and cellular longevity 2021, Vol.2021 (1), p.5577541-5577541
Main Authors: Jiménez-Delgado, Alicia, Ortiz, Genaro Gabriel, Delgado-Lara, Daniela L., González-Usigli, Hector Alberto, González-Ortiz, Luis Javier, Cid-Hernández, Margarita, Cruz-Serrano, José Antonio, Pacheco-Moisés, Fermín Paul
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c448t-afa5a28ac266e752309504d94deecf7e518bd2698465137a6f64c0ab4447b0ff3
cites cdi_FETCH-LOGICAL-c448t-afa5a28ac266e752309504d94deecf7e518bd2698465137a6f64c0ab4447b0ff3
container_end_page 5577541
container_issue 1
container_start_page 5577541
container_title Oxidative medicine and cellular longevity
container_volume 2021
creator Jiménez-Delgado, Alicia
Ortiz, Genaro Gabriel
Delgado-Lara, Daniela L.
González-Usigli, Hector Alberto
González-Ortiz, Luis Javier
Cid-Hernández, Margarita
Cruz-Serrano, José Antonio
Pacheco-Moisés, Fermín Paul
description Mitochondrial dysfunction and oxidative stress are extensively linked to Parkinson’s disease (PD) pathogenesis. Melatonin is a pleiotropic molecule with antioxidant and neuroprotective effects. The aim of this study was to evaluate the effect of melatonin on oxidative stress markers, mitochondrial complex 1 activity, and mitochondrial respiratory control ratio in patients with PD. A double-blind, cross-over, placebo-controlled randomized clinical trial study was conducted in 26 patients who received either 25 mg of melatonin or placebo at noon and 30 min before bedtime for three months. At the end of the trial, in patients who received melatonin, we detected a significant diminution of lipoperoxides, nitric oxide metabolites, and carbonyl groups in plasma samples from PD patients compared with the placebo group. Conversely, catalase activity was increased significantly in comparison with the placebo group. Compared with the placebo group, the melatonin group showed significant increases of mitochondrial complex 1 activity and respiratory control ratio. The fluidity of the membranes was similar in the melatonin group and the placebo group at baseline and after three months of treatment. In conclusion, melatonin administration was effective in reducing the levels of oxidative stress markers and restoring the rate of complex I activity and respiratory control ratio without modifying membrane fluidity. This suggests that melatonin could play a role in the treatment of PD.
doi_str_mv 10.1155/2021/5577541
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8545577</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2589578623</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-afa5a28ac266e752309504d94deecf7e518bd2698465137a6f64c0ab4447b0ff3</originalsourceid><addsrcrecordid>eNp9kc9qVDEUh4NYbK3uXEvAjaBjk9zk5t6NMNRqCx0qqOtwJn-ctHeSNslM7a6v4ev5JOYy00FdGAJJOB8f5-SH0AtK3lEqxBEjjB4JIaXg9BE6oD1nE9L3_PHuTsg-eprzJSFtwzh9gvYbLoms6wDdnzhndcHR4ZkdoMTgA56apQ8-lwTFx4DrnvkS9SIGkzwMeKqLX_tyhyEYfPHDm8qtLf5Sks0ZzyBd2ZRxFX2uBRtKxre-LOorXfmQY_h1_zPjDz5byPYZ2nMwZPt8ex6ibx9Pvh6fTs4vPp0dT88nmvOuTMCBANaBZm1rpWAN6QXhpufGWu2kFbSbG9b2HW8FbSS0ruWawJxzLufEueYQvd94r1fzpTW6tpVgUNfJLyHdqQhe_V0JfqG-x7XqBB9_twpebwUp3qxsLmrps7bDAMHGVVZMdJWSXd9U9NU_6GVcpVDHG6leyK5lI_V2Q-kUc07W7ZqhRI3RqjFatY224i__HGAHP2RZgTcbYOGDgVv_f91vnhWu4g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2589578623</pqid></control><display><type>article</type><title>Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease</title><source>Wiley_OA刊</source><source>Publicly Available Content (ProQuest)</source><creator>Jiménez-Delgado, Alicia ; Ortiz, Genaro Gabriel ; Delgado-Lara, Daniela L. ; González-Usigli, Hector Alberto ; González-Ortiz, Luis Javier ; Cid-Hernández, Margarita ; Cruz-Serrano, José Antonio ; Pacheco-Moisés, Fermín Paul</creator><contributor>Cabello-Verrugio, Claudio ; Claudio Cabello-Verrugio</contributor><creatorcontrib>Jiménez-Delgado, Alicia ; Ortiz, Genaro Gabriel ; Delgado-Lara, Daniela L. ; González-Usigli, Hector Alberto ; González-Ortiz, Luis Javier ; Cid-Hernández, Margarita ; Cruz-Serrano, José Antonio ; Pacheco-Moisés, Fermín Paul ; Cabello-Verrugio, Claudio ; Claudio Cabello-Verrugio</creatorcontrib><description>Mitochondrial dysfunction and oxidative stress are extensively linked to Parkinson’s disease (PD) pathogenesis. Melatonin is a pleiotropic molecule with antioxidant and neuroprotective effects. The aim of this study was to evaluate the effect of melatonin on oxidative stress markers, mitochondrial complex 1 activity, and mitochondrial respiratory control ratio in patients with PD. A double-blind, cross-over, placebo-controlled randomized clinical trial study was conducted in 26 patients who received either 25 mg of melatonin or placebo at noon and 30 min before bedtime for three months. At the end of the trial, in patients who received melatonin, we detected a significant diminution of lipoperoxides, nitric oxide metabolites, and carbonyl groups in plasma samples from PD patients compared with the placebo group. Conversely, catalase activity was increased significantly in comparison with the placebo group. Compared with the placebo group, the melatonin group showed significant increases of mitochondrial complex 1 activity and respiratory control ratio. The fluidity of the membranes was similar in the melatonin group and the placebo group at baseline and after three months of treatment. In conclusion, melatonin administration was effective in reducing the levels of oxidative stress markers and restoring the rate of complex I activity and respiratory control ratio without modifying membrane fluidity. This suggests that melatonin could play a role in the treatment of PD.</description><identifier>ISSN: 1942-0900</identifier><identifier>EISSN: 1942-0994</identifier><identifier>DOI: 10.1155/2021/5577541</identifier><identifier>PMID: 34707777</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Acids ; Alzheimer's disease ; Antioxidants ; Antioxidants - adverse effects ; Antioxidants - therapeutic use ; Antiparkinson Agents - adverse effects ; Antiparkinson Agents - therapeutic use ; Biomarkers - blood ; Blood platelets ; Cell Respiration - drug effects ; Clinical trials ; Cross-Over Studies ; Double-Blind Method ; Electron Transport Complex I - metabolism ; Enzymes ; Humans ; Lipid Peroxidation - drug effects ; Melatonin ; Melatonin - adverse effects ; Melatonin - therapeutic use ; Metabolites ; Mexico ; Mitochondria - drug effects ; Mitochondria - metabolism ; Movement disorders ; Neurons ; Oxidative stress ; Oxidative Stress - drug effects ; Parkinson Disease - blood ; Parkinson Disease - diagnosis ; Parkinson Disease - drug therapy ; Parkinson's disease ; Plasma ; Potassium ; Proteins ; Software ; Statistical analysis ; Time Factors ; Treatment Outcome</subject><ispartof>Oxidative medicine and cellular longevity, 2021, Vol.2021 (1), p.5577541-5577541</ispartof><rights>Copyright © 2021 Alicia Jiménez-Delgado et al.</rights><rights>Copyright © 2021 Alicia Jiménez-Delgado et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2021 Alicia Jiménez-Delgado et al. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-afa5a28ac266e752309504d94deecf7e518bd2698465137a6f64c0ab4447b0ff3</citedby><cites>FETCH-LOGICAL-c448t-afa5a28ac266e752309504d94deecf7e518bd2698465137a6f64c0ab4447b0ff3</cites><orcidid>0000-0002-7054-3313 ; 0000-0002-0343-1442 ; 0000-0002-1968-4815 ; 0000-0002-1861-6829 ; 0000-0002-3906-9051 ; 0000-0002-3735-4481 ; 0000-0002-8988-7570 ; 0000-0002-3769-5649</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2589578623/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2589578623?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,4024,25753,27923,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34707777$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Cabello-Verrugio, Claudio</contributor><contributor>Claudio Cabello-Verrugio</contributor><creatorcontrib>Jiménez-Delgado, Alicia</creatorcontrib><creatorcontrib>Ortiz, Genaro Gabriel</creatorcontrib><creatorcontrib>Delgado-Lara, Daniela L.</creatorcontrib><creatorcontrib>González-Usigli, Hector Alberto</creatorcontrib><creatorcontrib>González-Ortiz, Luis Javier</creatorcontrib><creatorcontrib>Cid-Hernández, Margarita</creatorcontrib><creatorcontrib>Cruz-Serrano, José Antonio</creatorcontrib><creatorcontrib>Pacheco-Moisés, Fermín Paul</creatorcontrib><title>Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease</title><title>Oxidative medicine and cellular longevity</title><addtitle>Oxid Med Cell Longev</addtitle><description>Mitochondrial dysfunction and oxidative stress are extensively linked to Parkinson’s disease (PD) pathogenesis. Melatonin is a pleiotropic molecule with antioxidant and neuroprotective effects. The aim of this study was to evaluate the effect of melatonin on oxidative stress markers, mitochondrial complex 1 activity, and mitochondrial respiratory control ratio in patients with PD. A double-blind, cross-over, placebo-controlled randomized clinical trial study was conducted in 26 patients who received either 25 mg of melatonin or placebo at noon and 30 min before bedtime for three months. At the end of the trial, in patients who received melatonin, we detected a significant diminution of lipoperoxides, nitric oxide metabolites, and carbonyl groups in plasma samples from PD patients compared with the placebo group. Conversely, catalase activity was increased significantly in comparison with the placebo group. Compared with the placebo group, the melatonin group showed significant increases of mitochondrial complex 1 activity and respiratory control ratio. The fluidity of the membranes was similar in the melatonin group and the placebo group at baseline and after three months of treatment. In conclusion, melatonin administration was effective in reducing the levels of oxidative stress markers and restoring the rate of complex I activity and respiratory control ratio without modifying membrane fluidity. This suggests that melatonin could play a role in the treatment of PD.</description><subject>Acids</subject><subject>Alzheimer's disease</subject><subject>Antioxidants</subject><subject>Antioxidants - adverse effects</subject><subject>Antioxidants - therapeutic use</subject><subject>Antiparkinson Agents - adverse effects</subject><subject>Antiparkinson Agents - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Blood platelets</subject><subject>Cell Respiration - drug effects</subject><subject>Clinical trials</subject><subject>Cross-Over Studies</subject><subject>Double-Blind Method</subject><subject>Electron Transport Complex I - metabolism</subject><subject>Enzymes</subject><subject>Humans</subject><subject>Lipid Peroxidation - drug effects</subject><subject>Melatonin</subject><subject>Melatonin - adverse effects</subject><subject>Melatonin - therapeutic use</subject><subject>Metabolites</subject><subject>Mexico</subject><subject>Mitochondria - drug effects</subject><subject>Mitochondria - metabolism</subject><subject>Movement disorders</subject><subject>Neurons</subject><subject>Oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Parkinson Disease - blood</subject><subject>Parkinson Disease - diagnosis</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson's disease</subject><subject>Plasma</subject><subject>Potassium</subject><subject>Proteins</subject><subject>Software</subject><subject>Statistical analysis</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1942-0900</issn><issn>1942-0994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kc9qVDEUh4NYbK3uXEvAjaBjk9zk5t6NMNRqCx0qqOtwJn-ctHeSNslM7a6v4ev5JOYy00FdGAJJOB8f5-SH0AtK3lEqxBEjjB4JIaXg9BE6oD1nE9L3_PHuTsg-eprzJSFtwzh9gvYbLoms6wDdnzhndcHR4ZkdoMTgA56apQ8-lwTFx4DrnvkS9SIGkzwMeKqLX_tyhyEYfPHDm8qtLf5Sks0ZzyBd2ZRxFX2uBRtKxre-LOorXfmQY_h1_zPjDz5byPYZ2nMwZPt8ex6ibx9Pvh6fTs4vPp0dT88nmvOuTMCBANaBZm1rpWAN6QXhpufGWu2kFbSbG9b2HW8FbSS0ruWawJxzLufEueYQvd94r1fzpTW6tpVgUNfJLyHdqQhe_V0JfqG-x7XqBB9_twpebwUp3qxsLmrps7bDAMHGVVZMdJWSXd9U9NU_6GVcpVDHG6leyK5lI_V2Q-kUc07W7ZqhRI3RqjFatY224i__HGAHP2RZgTcbYOGDgVv_f91vnhWu4g</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Jiménez-Delgado, Alicia</creator><creator>Ortiz, Genaro Gabriel</creator><creator>Delgado-Lara, Daniela L.</creator><creator>González-Usigli, Hector Alberto</creator><creator>González-Ortiz, Luis Javier</creator><creator>Cid-Hernández, Margarita</creator><creator>Cruz-Serrano, José Antonio</creator><creator>Pacheco-Moisés, Fermín Paul</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7054-3313</orcidid><orcidid>https://orcid.org/0000-0002-0343-1442</orcidid><orcidid>https://orcid.org/0000-0002-1968-4815</orcidid><orcidid>https://orcid.org/0000-0002-1861-6829</orcidid><orcidid>https://orcid.org/0000-0002-3906-9051</orcidid><orcidid>https://orcid.org/0000-0002-3735-4481</orcidid><orcidid>https://orcid.org/0000-0002-8988-7570</orcidid><orcidid>https://orcid.org/0000-0002-3769-5649</orcidid></search><sort><creationdate>2021</creationdate><title>Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease</title><author>Jiménez-Delgado, Alicia ; Ortiz, Genaro Gabriel ; Delgado-Lara, Daniela L. ; González-Usigli, Hector Alberto ; González-Ortiz, Luis Javier ; Cid-Hernández, Margarita ; Cruz-Serrano, José Antonio ; Pacheco-Moisés, Fermín Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-afa5a28ac266e752309504d94deecf7e518bd2698465137a6f64c0ab4447b0ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acids</topic><topic>Alzheimer's disease</topic><topic>Antioxidants</topic><topic>Antioxidants - adverse effects</topic><topic>Antioxidants - therapeutic use</topic><topic>Antiparkinson Agents - adverse effects</topic><topic>Antiparkinson Agents - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Blood platelets</topic><topic>Cell Respiration - drug effects</topic><topic>Clinical trials</topic><topic>Cross-Over Studies</topic><topic>Double-Blind Method</topic><topic>Electron Transport Complex I - metabolism</topic><topic>Enzymes</topic><topic>Humans</topic><topic>Lipid Peroxidation - drug effects</topic><topic>Melatonin</topic><topic>Melatonin - adverse effects</topic><topic>Melatonin - therapeutic use</topic><topic>Metabolites</topic><topic>Mexico</topic><topic>Mitochondria - drug effects</topic><topic>Mitochondria - metabolism</topic><topic>Movement disorders</topic><topic>Neurons</topic><topic>Oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Parkinson Disease - blood</topic><topic>Parkinson Disease - diagnosis</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson's disease</topic><topic>Plasma</topic><topic>Potassium</topic><topic>Proteins</topic><topic>Software</topic><topic>Statistical analysis</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiménez-Delgado, Alicia</creatorcontrib><creatorcontrib>Ortiz, Genaro Gabriel</creatorcontrib><creatorcontrib>Delgado-Lara, Daniela L.</creatorcontrib><creatorcontrib>González-Usigli, Hector Alberto</creatorcontrib><creatorcontrib>González-Ortiz, Luis Javier</creatorcontrib><creatorcontrib>Cid-Hernández, Margarita</creatorcontrib><creatorcontrib>Cruz-Serrano, José Antonio</creatorcontrib><creatorcontrib>Pacheco-Moisés, Fermín Paul</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oxidative medicine and cellular longevity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiménez-Delgado, Alicia</au><au>Ortiz, Genaro Gabriel</au><au>Delgado-Lara, Daniela L.</au><au>González-Usigli, Hector Alberto</au><au>González-Ortiz, Luis Javier</au><au>Cid-Hernández, Margarita</au><au>Cruz-Serrano, José Antonio</au><au>Pacheco-Moisés, Fermín Paul</au><au>Cabello-Verrugio, Claudio</au><au>Claudio Cabello-Verrugio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease</atitle><jtitle>Oxidative medicine and cellular longevity</jtitle><addtitle>Oxid Med Cell Longev</addtitle><date>2021</date><risdate>2021</risdate><volume>2021</volume><issue>1</issue><spage>5577541</spage><epage>5577541</epage><pages>5577541-5577541</pages><issn>1942-0900</issn><eissn>1942-0994</eissn><abstract>Mitochondrial dysfunction and oxidative stress are extensively linked to Parkinson’s disease (PD) pathogenesis. Melatonin is a pleiotropic molecule with antioxidant and neuroprotective effects. The aim of this study was to evaluate the effect of melatonin on oxidative stress markers, mitochondrial complex 1 activity, and mitochondrial respiratory control ratio in patients with PD. A double-blind, cross-over, placebo-controlled randomized clinical trial study was conducted in 26 patients who received either 25 mg of melatonin or placebo at noon and 30 min before bedtime for three months. At the end of the trial, in patients who received melatonin, we detected a significant diminution of lipoperoxides, nitric oxide metabolites, and carbonyl groups in plasma samples from PD patients compared with the placebo group. Conversely, catalase activity was increased significantly in comparison with the placebo group. Compared with the placebo group, the melatonin group showed significant increases of mitochondrial complex 1 activity and respiratory control ratio. The fluidity of the membranes was similar in the melatonin group and the placebo group at baseline and after three months of treatment. In conclusion, melatonin administration was effective in reducing the levels of oxidative stress markers and restoring the rate of complex I activity and respiratory control ratio without modifying membrane fluidity. This suggests that melatonin could play a role in the treatment of PD.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>34707777</pmid><doi>10.1155/2021/5577541</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7054-3313</orcidid><orcidid>https://orcid.org/0000-0002-0343-1442</orcidid><orcidid>https://orcid.org/0000-0002-1968-4815</orcidid><orcidid>https://orcid.org/0000-0002-1861-6829</orcidid><orcidid>https://orcid.org/0000-0002-3906-9051</orcidid><orcidid>https://orcid.org/0000-0002-3735-4481</orcidid><orcidid>https://orcid.org/0000-0002-8988-7570</orcidid><orcidid>https://orcid.org/0000-0002-3769-5649</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1942-0900
ispartof Oxidative medicine and cellular longevity, 2021, Vol.2021 (1), p.5577541-5577541
issn 1942-0900
1942-0994
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8545577
source Wiley_OA刊; Publicly Available Content (ProQuest)
subjects Acids
Alzheimer's disease
Antioxidants
Antioxidants - adverse effects
Antioxidants - therapeutic use
Antiparkinson Agents - adverse effects
Antiparkinson Agents - therapeutic use
Biomarkers - blood
Blood platelets
Cell Respiration - drug effects
Clinical trials
Cross-Over Studies
Double-Blind Method
Electron Transport Complex I - metabolism
Enzymes
Humans
Lipid Peroxidation - drug effects
Melatonin
Melatonin - adverse effects
Melatonin - therapeutic use
Metabolites
Mexico
Mitochondria - drug effects
Mitochondria - metabolism
Movement disorders
Neurons
Oxidative stress
Oxidative Stress - drug effects
Parkinson Disease - blood
Parkinson Disease - diagnosis
Parkinson Disease - drug therapy
Parkinson's disease
Plasma
Potassium
Proteins
Software
Statistical analysis
Time Factors
Treatment Outcome
title Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A14%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Melatonin%20Administration%20on%20Mitochondrial%20Activity%20and%20Oxidative%20Stress%20Markers%20in%20Patients%20with%20Parkinson%E2%80%99s%20Disease&rft.jtitle=Oxidative%20medicine%20and%20cellular%20longevity&rft.au=Jim%C3%A9nez-Delgado,%20Alicia&rft.date=2021&rft.volume=2021&rft.issue=1&rft.spage=5577541&rft.epage=5577541&rft.pages=5577541-5577541&rft.issn=1942-0900&rft.eissn=1942-0994&rft_id=info:doi/10.1155/2021/5577541&rft_dat=%3Cproquest_pubme%3E2589578623%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c448t-afa5a28ac266e752309504d94deecf7e518bd2698465137a6f64c0ab4447b0ff3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2589578623&rft_id=info:pmid/34707777&rfr_iscdi=true